Junshi Biosciences Announces NDA Acceptance in Hong Kong for...
UK, Australia, Singapore, Malaysia and Hong Kong Special Administrative Region (“SAR”). Furthermore, NDAs for toripalimab have also been submitted in India, South Africa, Chile and Jordan.